http://www.gosreports.com
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review 2021 by Gosreports
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Full Report:
http://www.gosreports.com/global-residential-air-purifiers-market-research-report-2016/
http://www.gosreports.com/global-new-energy-vehicles-market-research-report-2016/
The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of contents:
Table of Contents
Table of Contents 2
Introduction 8
Chronic Obstructive Pulmonary Disease (COPD) Overview 9
Therapeutics Development 10
Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics under Development by Companies 12
Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics under Investigation by Universities/Institutes 22
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Products Glance 23
Chronic Obstructive Pulmonary Disease (COPD) – Products under Development by Companies 27
Chronic Obstructive Pulmonary Disease (COPD) – Products under Investigation by Universities/Institutes 40
Chronic Obstructive Pulmonary Disease (COPD) – Companies Involved in Therapeutics Development 41
Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics Assessment 146
Drug Profiles 177
Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects 505
Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products 529
Chronic Obstructive Pulmonary Disease (COPD) – Product Development Milestones 536
Appendix 554″ “List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 35
Number of Products under Development by Companies, H2 2016 (Contd..1) 36
Number of Products under Development by Companies, H2 2016 (Contd..2) 37
Number of Products under Development by Companies, H2 2016 (Contd..3) 38
Number of Products under Development by Companies, H2 2016 (Contd..4) 39
Number of Products under Development by Companies, H2 2016 (Contd..5) 40
Number of Products under Development by Companies, H2 2016 (Contd..6) 41
Number of Products under Development by Companies, H2 2016 (Contd..7) 42
Number of Products under Development by Companies, H2 2016 (Contd..8) 43
Number of Products under Investigation by Universities/Institutes, H2 2016 44
Comparative Analysis by Late Stage Development, H2 2016 45
Comparative Analysis by Clinical Stage Development, H2 2016 46
Comparative Analysis by Early Stage Development, H2 2016 47
Comparative Analysis by Unknown Stage Development, H2 2016 48
Products under Development by Companies, H2 2016 49
Products under Development by Companies, H2 2016 (Contd..1) 50
Products under Development by Companies, H2 2016 (Contd..2) 51
Products under Development by Companies, H2 2016 (Contd..3) 52
Products under Development by Companies, H2 2016 (Contd..4) 53
Products under Development by Companies, H2 2016 (Contd..5) 54
Products under Development by Companies, H2 2016 (Contd..6) 55
Products under Development by Companies, H2 2016 (Contd..7) 56
Products under Development by Companies, H2 2016 (Contd..8) 57
Products under Development by Companies, H2 2016 (Contd..9) 58
Products under Development by Companies, H2 2016 (Contd..10) 59
Products under Development by Companies, H2 2016 (Contd..11) 60
Products under Development by Companies, H2 2016 (Contd..12) 61
Products under Investigation by Universities/Institutes, H2 2016 62
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AB2 Bio Ltd., H2 2016 63
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Abeona Therapeutics, Inc. , H2 2016 64
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 65
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 66
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 67
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Advinus Therapeutics Ltd, H2 2016 68
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AlgiPharma AS, H2 2016 69
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Allinky Biopharma, H2 2016 70
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Alteogen Inc., H2 2016 71
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Amakem NV, H2 2016 72
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 73
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Angion Biomedica Corp., H2 2016 74
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Apellis Pharmaceuticals Inc, H2 2016 75
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 76
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Astellas Pharma Inc., H2 2016 77
……………………
More Information:
http://www.gosreports.com/global-fatty-amine-market-research-report-2016/

Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com